The company will present study results in support of its
With the growing volumes of peer-reviewed literature reporting the relationships between genomic aberrations, tumor responsiveness to treatments, and associated patient outcomes, there has been a significant increase in the challenges facing clinicians to comprehensively identify and prioritize personalized treatments. To overcome such challenges, MolecularHealth developed a proprietary, automated computational system to assess the predicted effects of published genomic aberrations on drug responsiveness in a patient/disease-specific manner.
Dr. Jackson’s presentation, titled,“Automated Retrieval and Assessment of Biomarker-related Evidence for Cancer Treatment Decision Support,” will reveal supporting results of a study demonstrating the accuracy and efficiency of MolecularHealth’s analytics engine in assessing patient-relevant evidence, compared to a human expert with access to the same body of data.
MolecularHealth’s cancer treatment decision support offering, TreatmentMAP™, is based on this analytics engine and combines precision medicine with advanced data analysis to guide physicians to the safest and most effective cancer treatment options for their patients. The platform was commercially launched in
The abstract, poster board number A41, is scheduled to be presented as follows:
Date: Friday, June 20th
Session: Poster Session A
Location: Grand Cypress Ballroom GHI
Presenters: David Jackson, Ph.D.,
The abstract will also be published in Proceedings, an AACR publication. This year’s conference will focus on Drug Sensitivity and Resistance: Improving Cancer Therapy and will be held on June 18th through the 21st at the
MolecularHealth is a leading biomedical company that is transforming molecular data into clinically actionable information to inform the most efficient and safest cancer treatment options for each individual cancer patient.
In the U.S., TreatmentMAPTM is a laboratory developed test (LDT) performed at MolecularHealth’s
MolecularHealth, comprised of a multidisciplinary team of oncologists, scientists, businesspeople, and IT experts with long-standing expertise in their fields, works in partnership with some of the world’s leading healthcare, information technology and NGS companies, including the
Located in the centers of cancer research in
Please visit www.molecularhealth.com for more information and follow on Twitter at www.twitter.com/molecularhealth.
Contact for U.S.:
Associate Vice President
Contact for EU: